Specjalistyczna Praktyka Lekarska Slawomir Mandziuk
- Address
- lock Available on a paid plan
Specjalistyczna Praktyka Lekarska Slawomir Mandziuk - Advanced Lung Cancer Research
Specjalistyczna Praktyka Lekarska Slawomir Mandziuk is a specialized medical practice dedicated to advancing treatment options for patients with complex oncological conditions. The center demonstrates particular expertise in conducting cutting-edge clinical trials for advanced non-small cell lung cancer (NSCLC), focusing on molecularly targeted therapies for patients with specific genetic mutations.
- KRAS G12C mutation-targeted therapies in metastatic NSCLC
- Phase 3 comparative efficacy studies in previously treated lung cancer patients
- Novel investigational agents versus standard chemotherapy regimens
The practice's research portfolio reflects a commitment to precision oncology, particularly in evaluating innovative targeted therapeutic agents for patients with advanced lung cancer who have exhausted initial treatment options. By participating in pivotal Phase 3 trials comparing molecularly targeted drugs with conventional chemotherapy, the center contributes valuable data to inform treatment decisions for patients with specific genetic alterations in their tumors.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Regeneron Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Specjalistyczna Praktyka Lekarska Slawomir Mandziuk
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 2 Evaluation of Cemiplimab and BNT116 Combination Versus Cemiplimab Monotherapy in Advanced NSCLC with PD-L1 Expression ≥50% | Regeneron Pharmaceuticals Inc. | Phase II | Not Yet Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adagrasib | 1 | Unknown | 2020-12-23 | 2020-12-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.